If you are an executive within a large life-science company, here's your chance to access Pittsburgh’s diverse pool of leading-edge life-sciences talent and technology – from early-stage research to ready-to-pilot startups. Each innovator has been invited for their ability to bring opportunities that can transform the healthcare industry. This unique program, organized by Innovation Works, is part of the region’s weeklong Life Sciences Pittsburgh activities (May 13-17, 2019).
Gain early access and make important connections with entrepreneurs and principal researchers exploring digital-enabled, transformative technologies in areas that include:
• Neuro-robotics and neuro-sensors
• AI/ML applications including biomedical research and business operations
• Bio-printing and 3D printing
• Organic and bio-hybrid robotics
• Behavioral health & smart technologies
• Expert systems & decision support
• Plant-based materials for skin substitutes
...and more
Sample descriptions of research and startup opportunities are included below
Corporations committing to participation by May 8 can also opt into helping to choose the researchers and startups from our applicant pool – for an experience even more targeted to your company’s needs. Program participation includes up to two executives for the day, with your own customized schedule of meetings.
These examples represent some of the 15+ university researchers from which corporate partners can select their individual sessions on May 15. Opportunities exist for research collaboration and/or technology commercialization.
Carnegie Mellon University is world-renowned in artificial intelligence, machine learning, robotics and more. CMU researchers will be sharing emerging technologies for the application of these technologies in life sciences.
The University of Pittsburgh is a world-class research institution with over $500M in 2018 NIH funding. Pitt researchers will share emerging technologies digital-enabled therapies, neural implants and more.
Research on computational mass spectrometry and metagenomics for antibiotic discovery and microbiome analysis. Analyzing large scale mass spectrometry and metagenomics data using machine learning, genome mining, signal processing, graph theory and statistics to discover novel genetically synthesized small molecules.
The platform we have built enables truly ubiquitous sensing applications. We have been approached by a number of companies in the health care at home space, who want to track activities of daily living to improve senior care at home. Our platform can also be used for other healthcare uses cases as well.
Establishing techniques for farming organic materials for robotic applications from aquatic invertebrates and well as developing housings and maturation platforms for engineering bioactuators. Research focuses on the use of organic materials as structures, actuators, sensors, and controllers towards the development of biohybrid and organic robots and biohybrid prosthetics.
This NSF-STTR-funded startup company has developed non-invasive neural sensing technologies. Includes device that is portable, wireless, easy and quick to apply, and allows diagnosis and better treatment of neural disorders. The IP covers algorithms and architectures for collection of high-precision neural signal data, algorithms to detect indications of traumatic brain injury, and novel electrode materials.
Uses patented approach of printing within a support gel, rather than in air, allowing the design and fabrication of unlimited geometries and multiple materials embedded within one another in a single print. Our technology has many applications, including bioprinting of collagen medical devices and scaffolds for regeneration.
Early-stage startup that reformulates FDA-approved drugs and creates new, long-acting injectable (LAI) medications with improved clinical and economic benefits. LAI drug release is achieved via polymer micro-particle encapsulation. Computational Drug Delivery™ technology includes artificial intelligence (AI) based predictive modeling software.
Growth-stage company analyzes genetic, clinical and behavioral information to determine biological dysfunction driving patients' chronic condition and aligns therapeutics to restore function. Have created an end to end solution that can inform treatment from the emergency department to the clinic and through long-term disease management.
